NfL is an extraordinarily prospective biomarker as a single measure for differentiating APD (MSA and PSP) from PD and HCs as well as differentiating MSA from PSP, with high sensitivity and specificity. Here, NEFL is linked to supranuclear palsy, progressive, 1.